International reporting scale of BCR-ABL1 fusion transcript in chronic myeloid leukemia: first report from India

Balasubramanian, Poonkuzhali ; Chendamarai, Ezhilarasi ; Markose, Preetha ; Fletcher, Linda ; Branford, Susan ; George, Biju ; Mathews, Vikram ; Chandy, Mammen ; Srivastava, Alok (2012) International reporting scale of BCR-ABL1 fusion transcript in chronic myeloid leukemia: first report from India Acta Haematologica, 127 (3). pp. 135-142. ISSN 0001-5792

Full text not available from this repository.

Official URL: https://www.karger.com/Article/Abstract/334716

Related URL: http://dx.doi.org/10.1159/000334716

Abstract

Achieving a major molecular response (MMR) is an important predictor of progression-free survival in chronic myeloid leukemia patients treated with imatinib. This requires accurate measurement of BCR-ABL1 transcripts normalized to a control gene, as well as defining a level (BCR-ABL1/control gene ratio) that will correlate with sustained clinical response. To make these measurements comparable between laboratories, an international scale (IS) is necessary. A BCR-ABL1/control gene ratio of 0.10% represents MMR in the IS. In collaboration with an international reference laboratory in Adelaide, S.A., Australia, we have established and validated a lab-specific conversion factor for expressing BCR-ABL1 transcript levels in the IS. In this report, we explain the process and steps involved in obtaining a valid lab-specific conversion factor for expressing BCR-ABL1 transcript levels in the IS.

Item Type:Article
Source:Copyright of this article belongs to Karger Publisher.
Keywords:Chronic Myeloid Leukemia; Complete Cytogenetic Response; BCR-ABL1 Transcripts; Major Molecular Response
ID Code:113854
Deposited On:07 Jun 2018 11:19
Last Modified:08 Jun 2018 07:45

Repository Staff Only: item control page